Pharma News

How COVID-19 M&A performed in the pharmaceutical industry in Q2 2023

In value terms, COVID-19-related deal activity remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume increased by 75% in Q2 2023 versus the previous quarter and was 250% higher than in Q2 2022.

The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Computershare; Ernst & Young Global; MTS Health Partners with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Gibson, Dunn & Crutcher; Latham & Watkins; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC with 1, 1, 1 deals respectively.

For further understanding of GlobalData’s COVID-19 Impact on Medical Devices Industry – Thematic Research, buy the report here.

This content was updated on 18 July 2023




Source link
#COVID19 #performed #pharmaceutical #industry

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *